FY 2022 Financial Results Announced Indivior PLC (LSE: INDV) today announced 2022 Full Year Results. The earnings release, investor presentation, and webcast are available at...
Thursday, February 16, 2023 2 min read
Key Takeaway: Indivior PLC has announced its full year financial results for 2022, highlighting its ongoing commitment to developing treatments for substance use disorders and serious mental illnesses. The company plans to discuss these results in a live webcast, emphasizing its efforts in providing evidence-based treatment across the globe. Indivior continues to strengthen its position in the market with a diverse pipeline aimed at expanding its product offerings.
Market Sentiment Analysis
POSITIVE FACTORS
Indivior announced its financial results for FY 2022, indicating strong performance.
The company is dedicated to addressing substance use disorders and serious mental illnesses.
Indivior has a diverse pipeline to tackle chronic conditions and related disorders.
CONCERNS & RISKS
No specific negative aspects were mentioned in the article.
Full Press Release Details
SLOUGH, England and RICHMOND, Va. , Feb. 16, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced 2022 Full Year Results. The earnings release, investor presentation, and webcast are available at www.indivior.com .
There will be a live webcast presentation on February 16, 2023 , at 8:00 am EST / 13:00 GMT . The details are below.
Participants may access the presentation telephonically with the following link:
Registrants will have an option to be called back immediately prior to the call or be provided with a call-in # with a unique pin code following their registration.
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid use disorder treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and cooccurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in 39 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .
SOURCE Indivior PLC
21 %
Frequently Asked Questions
What were the 2022 Full Year results for Indivior?
Indivior announced their 2022 Full Year results on February 16, 2023.
Is there a live webcast for the presentation?
Yes, a live webcast took place on February 16, 2023, at 8:00 am EST.
What is Indivior's primary focus?
Indivior focuses on developing medicines for substance use disorders and mental illnesses.
How many countries offer Indivior's products?
Indivior's products are available in 39 countries worldwide.
Where is Indivior headquartered?
Indivior is headquartered in Richmond, Virginia, USA.